Rocket Pharma (RCKT) P/E Multiple

Symbol and logo of brand Rocket Pharmaceuticals Inc (RCKT)

This price chart for Rocket Pharmaceuticals (RCKT) reflects the performance of a company developing gene therapies for cardiovascular and blood pathologies (KRESLADI), where the P/E ratio stands at -15.70. The business leverages a shortage of modern treatments for hereditary diseases and strong interest from specialized clinics. Risks are mitigated by a broad development portfolio aimed at treating children with genetic disorders.

RCKT Rocket Corp: Price to Earnings Ratio in the range 07/04/2022 - 11/12/2026

Analytical breakdowns for Rocket Pharmaceuticals

- stock value and consensus price forecast:
Stock Quotes rocketpharma.com|RCKT - Price Target Chart
- market capitalization details:
Market Capitalization Rocket Pharmaceuticals, Inc.|RCKT - Enterprise Value
- company book value details:
Net Asset Value per Share Rocket Pharmaceuticals|RCKT - Company Net Assets|Market Cap to Book Value Multiple rocketpharma.com|RCKT - Cumulative Company Assets
- debt and solvency information:
All Debt to Shareholders' Equity Ratio Rocket Pharmaceuticals|RCKT - Long-Term Debt to Equity|Current Liabilities to Equity Rocket Corp|RCKT - Company Aggregate Debts|Debt to Net Assets Ratio Rocket Pharmaceuticals, Inc.|RCKT - Company Long-Term Debts|Company Short-Term Debts Rocket Pharmaceuticals|Intermediate Coverage Ratio rocketpharma.com
- business earnings and investment ratios data:
RCKT - Company Net Income|Future Profit Rocket Pharmaceuticals|RCKT - P/E Multiple|Forward P/E Multiple Rocket Pharma|RCKT - PEG Multiple|Enterprise Value to EBITDA Ratio Rocket Pharmaceuticals, Inc.|RCKT - Operating profit EBITDA|Net earnings per one share for the last twelve months Rocket Pharmaceuticals|RCKT - Net earnings per share for the last 12 months|Quarterly EPS earnings growth rocketpharma.com|RCKT - Net earnings per share growth this year|Projected earnings per share increase next year Rocket Pharmaceuticals
Summary company analysis:rocketpharma.com - RCKT
Flagship merchandise of Rocket Pharma

The P/E ratio reflects the cost of a single unit of profit by comparing the market value of the business with its actual financial result. For Rocket Pharmaceuticals (RCKT), this calculation is complicated by high clinical trial costs prior to the commercialization stage of gene therapy. By analyzing the company's P/E ratio, an investor can see the impact of rising unit costs on the valuation. The long-term consensus requires comparing the multiple with the potential for future sales.

Key competitors

Price to Earnings Ratio Tempus AI Inc (TEM)|Price to Earnings Ratio Qiagen (QGEN)|P/E Multiple Ionis Pharmaceuticals, Inc. (IONS)|P/E Multiple RGEN (Repligen Corp.)|Avidity Corp (RNA) - Market Cap to Earnings|CRSP: Price to Earnings Ratio|genedx.com - Market Price to Net Income Ratio|RARE (Ultragenyx) - Price to Earnings Ratio|Beam Therapeutics Inc - Company Value to Net Income|Price to Earnings Ratio Sarepta Therapeutics Inc|Twist Bioscience Corp - Market Cap to Net Income|P/E Multiple TXG|NTLA (intelliatx.com) - Company Value to Net Income|P/E Multiple STOK (Stoke Therapeutics, Inc.)|P/E Multiple BioLife Solutions Inc BLFS|WVE - Price to Earnings Ratio|Company Value to Net Income MAZE (Maze Therapeutics Corp)|Sionna Therapeutics Inc (SION) - Price to Earnings Ratio|Price to Earnings Ratio primemedicine.com|TSHA (Taysha Gene Therapies, Inc.) - P/E Multiple|P/E Multiple uniQure NV|P/E Multiple MGTX|Price to Earnings Ratio REGENXBIO Corp RGNX|P/E Multiple SLDB (Solid Biosciences Inc.)|ocugen.com (OCGN) - Market Cap to Earnings|PACB: Price to Earnings Ratio|BNTC - P/E Multiple|DSGN (Design Pharma) - Price to Earnings Ratio|FDMT: Market Price to Net Income Ratio|LXEO (Lexeo Therapeutics Inc.) - P/E Multiple|Korro Bio, Inc (KRRO) - Business Payback Period|P/E Multiple EDIT|Price to Earnings Ratio Silence Therapeutics PLC SLN|P/E Multiple PRQR (ProQR Therapeutics)|P/E Multiple Codexis Inc CDXS|SGMO - Price to Earnings Ratio|NAUT: Price to Earnings Ratio|Metagenomi (MGX) - Price to Earnings Ratio|DTIL - Business Payback Period|Price to Earnings Ratio Generation Bio Co|BOLD: Company Value to Net Income|P/E Multiple XCUR|Price to Earnings Ratio imunon.com IMNN|Price to Earnings Ratio Phio Pharmaceuticals Corp. PHIO|P/E Multiple Mustang Bio Inc MBIO|RNAZ: Price to Earnings Ratio|Bionano Genomics, Inc. - Market Price to Net Income Ratio|APDN: P/E Multiple|Price to Earnings Multiple BLUE|Price to Earnings Ratio ImmunoPrecise Antibodies Ltd|Price to Earnings Multiple OMGA (Omega Therapeutics Inc)|P/E Multiple OMIC|P/E Multiple Regulus (RGLS)|Price to Earnings Ratio Syros Pharmaceuticals SYRS|Company Value to Net Income TBIO|TCON - Price to Earnings Ratio|Market Cap to Earnings Unity Biotechnology Inc.